10-Q · May 14, 2026
Mannatech, Inc. reported a decrease in revenue and a net loss in Q1 2026 compared to Q1 2025, with revenue of $24.9 million, down 6.2% year-over-year, and a net income of $1.0 million, improving from a net loss of $1.5…
Earnings analysis · 10-Q
MTEX earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so current-quarter revenue, margins, EPS, cash flow, and year-over-year trends cannot be…
Read full summary
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so current-quarter revenue, margins, EPS, cash flow, and year-over-year trends cannot be quantified. The most material disclosed development is the April 20, 2026 Nasdaq notice regarding the $2,500,000 minimum-equity requirement. Management reported effective disclosure controls as of June 30, 2026, but provided no quantitative forward guidance in the supplied filing text.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls remained effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported 0 material changes to internal control over financial reporting during the quarter.
-
Limited financial-instrument exposure
The filing states that the company has not issued any debt instruments and has not entered into forward, futures, option, or swap agreements, limiting disclosed exposure to certain financial market risks.
What to watch
-
Nasdaq minimum-equity deficiency
The company disclosed that it received an April 20, 2026 Nasdaq notice for noncompliance with Listing Rule 5550(b)(1), which requires at least $2,500,000 of stockholders’ equity. Failure to regain compliance could result in delisting and impair access to capital.
-
Tariff and trade-policy exposure
The filing adds or expands discussion of trade-policy risk involving the United States, Mexico, Canada, China, South Korea, and other countries. Tariffs, retaliation, or export restrictions could increase costs, disrupt shipments, and pressure profitability, with no quantified mitigation benefit provided.
-
Unhedged currency volatility
The company remains exposed to foreign-currency fluctuations because it translates international revenue and expenses at average exchange rates and does not use financial instruments to hedge that exposure. The filing states that future effects on results and cash flows cannot be predicted with certainty.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; outlook may be deferred to the earnings release or call.
Earlier filings 2
10-K · April 15, 2026
Mannatech positions itself as a network-marketing focused nutritional supplements company selling proprietary glyconutrient products (notably Ambrotose®, developed and patented in 1996) across three regions (Americas,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.